Genenta Science



GENENTA EVOLVING INTO SAENTRA FORGE

The Next-Generation Strategic Industrial Consolidator in Aerospace, Defense, National Security and Biotech.

© 2026 Genenta Science. All rights reserved worldwide

September 2026

Genenta Science

FORWARD-LOOKING STATEMENTS AND OTHER NOTICES

Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation are forward-looking statements. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech (Form 6-k filled on January 27, 2026), the funding provided by the recently acquired Mandatory Convertible Bond and related legal proceedings, clinical trial for newly diagnosed GBM patients, as well as Genenta’s ability to raise capital and/or establish partnerships to fund its research and development plans, etc. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2025, and Genenta's material disclosures on Form 6-K dated October 10, 2025, January 26, 2026, as well as other Form 6-K disclosures filed with the Securities and Exchange Commission. Forward-looking statements contained in this document are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

Non-GAAP Information. This document includes EBITDA (earnings before interest, taxes, depreciation, and amortization) which is a non-GAAP financial measure. EBITDA is defined as net loss adjusted to exclude interest income, income tax expense, and depreciation and amortization. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. Genenta believes that this non-GAAP financial measure, when considered together with financial information prepared in accordance with US GAAP, can enhance investors’ and analysts’ ability to meaningfully compare its results from period to period and to forward-looking guidance, and to identify operating trends in its business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with US GAAP. The Company is unable to provide a reconciliation of forward-looking EBITDA to the most directly comparable GAAP measure without unreasonable effort because certain items required for such reconciliation are outside the Company’s control and/or cannot be reasonably predicted.

Genenta Science

GENENTA TRANSFORMING INTO SAENTRA FORGE

In response to evolving market dynamics and opportunities, Genenta Science S.p.A. (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a **next-generation industrial consolidator** focused on acquiring **privately held businesses** operating in national-security **regulated sectors** contemplated by the Italian Golden Power legislation[1].

The Company is targeting **majority or full ownership in companies with established operating profitability**, typically generating up to approximately €5 million in EBITDA.

In this context, Genenta plans to adopt the new corporate name of **Saentra Forge S.p.A.** with a new Nasdaq ticker symbol of **SAEN[2]**.

1: Golden Power is Italy's investment screening framework — broadly comparable to CFIUS in the United States, the IEF regime in France, and the United Kingdom's NSI Act — and covers strategic domains such as biotechnology, biosecurity, defense, cybersecurity, AI-driven intelligence, aerospace, quantum technologies, secure communications, and critical infrastructure.
2: The new corporate name and the new Nasdaq ticker symbol pending effectiveness.

Genenta Science

THE STRATEGIC PILLARS

The Company will be organized around key synergistic pillars built



AEROSPACE

DEFENSE

NATIONAL SECURITY



BIOTECHNOLOGY

through strategic majority or full acquisitions, creating a diversified platform.

A STRUCTURAL ADVANTAGE

In strategically regulated sectors, the barrier that deters most buyers is our entry point not an obstacle, but a moat.



GOLDEN POWER = MOAT	ACCESS, NOT PRICE	SOVEREIGNTY-ALIGNED GOV.	PERMANENT, NO-EXIT CAPITAL	VALUE & TRANSPARENCY
Screening filters out most buyers	The right access, not the highest bid	Praexidia in governance · 5-yr lock-up[1]	National champions, held long-term	Private-market entry · Nasdaq-listed

1: Fondazione Praexidia is a private-law foundation bringing together senior figures from Italian government institutions, the defense industry and the armed forces. It is a long-term shareholder of the Company — shares received through a donation from the founder and CEO Pierluigi Paracchi — and is party to a shareholders' agreement providing consultation rights on significant corporate transactions and a renewable five-year lock-up, reinforcing governance stability and sovereignty-aligned continuity.

Genenta Science

WHY NOW: THE OPPORTUNITY

Italy's defense supply chain is a vast, fragmented base of SMEs – the headline figures capture only the tip



Genenta targets this base

~28	avg. employees per firm (vs 10 in manufacturing) — small, specialized⁵
+5%	supply-chain sales growth in 2025, above manufacturing⁵
≈€12.2B	additional Italian defense spend planned by 2028 (+~0.5pp of GDP)⁵

Everyone quotes the tip. Genenta's opportunity is the fragmented base — thousands of specialized SMEs to consolidate.

2: Mediobanca Area Studi, "Sistema Difesa nel mondo e in Italia," 2024 edition (FY2023 data).
5: Banca d'Italia, Annual Report 2025, box "La difesa in Italia" (FY2023 data; 2025 Invind survey).

Genenta Science

WHY NOW: THE OPPORTUNITY

Strategic value is leaving Italy just as a capital and demand surge into the sector. Genenta turns that gap into a consolidation aggregator.

THE RISK — VALUE LEAKING ABROAD

36/100 Top 100 defense firms foreign-controlled — 25.1% of sector revenue[2]

~2/3 of Italian PE exits since 2000 saw control pass to foreign buyers[1]

EXIT PE sells on a fixed clock and the buyer is often foreign, meaning loss of national capability — not just an asset

THE TAILWIND — CAPITAL & DEMAND ARRIVING

~$8.7B European DSR venture funding in 2025, up 55% YoY[3]

€800B EU resources under ReArm Europe / Readiness 2030 (up to)[4]

+5% Italian supply-chain sales in 2025; +~0.5pp GDP defense spend by 2028[5]

THE OPPORTUNITY — GENENTA, CONSOLIDATOR OF THE STRATEGIC SUPPLY CHAIN

Genenta acquires profitable, lower-EBITDA SMEs that traditional PE would resell outside Italy, and aggregates them onto a transparent, Nasdaq-listed platform — permanent capital, no forced exit, keeping strategic know-how in national hands.

The value is here. Without a national consolidation vehicle, it keeps leaving — that is the gap Genenta is built to fill.

1: Fondazione Praexidia–Banca Investis study (2026). 2: Mediobanca Area Studi, 2024 edition (FY2023). 3: Dealroom & NATO Innovation Fund, 2025 full-year.
4: European Commission, ReArm Europe / Readiness 2030 (2025); targets, not committed spending. 5: Banca d'Italia, Annual Report 2025, box "La difesa in Italia."

Genenta Science

ACQUISITION CRITERIA

A disciplined filter applied to strategic scale-up –
acquiring where private capital wants in but cannot easily access.

THE PIPELINE

THE FILTER

01 MAJORITY CONTROL
Targeting 51%+ ownership — full strategic control, not minority stakes.

02 ESTABLISHED PROFITABILITY
Positive operating profile, typically up to ~€5M EBITDA.

03 PRIVATELY HELD
Italian founder- and family-owned businesses facing a scale-up gap.

04 GOLDEN POWER SECTORS
Defense · Aerospace · Cybersecurity · Biotech / Biosecurity.

05 PRIVATE-MARKET VALUATIONS
Acquired at private-market prices, integrated into a Nasdaq-listed platform.

Genenta Science

VALUATION ARBITRAGE

The Genenta Science value creation model is based on multiple **valuation arbitrage**: acquiring companies at private market valuations, consolidating and accelerating their growth, and ultimately monetizing them through public market multiples through ownership in a Nasdaq-listed platform.

This approach unlocks significant hidden value, provides scalable exposure to mission-critical sectors, and generates superior returns in industries characterized by strong demand tailwinds and regulatory protection. Genenta is transitioning from a solely biotech business to an earnings and profits business.

LEADERSHIP

PIERLUIGI PARACCHI
Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University**.
Previously, he founded and led **Quantica SGR**, co-founded **Axòn Capital**, and served as Venture Consultant at **Sofinnova Partners**. He has also served on the Executive Committee of Federchimica–Assobiotec and is a Board Member of **InnovUp**.

+ 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic, and life science companies, including **Biological Dynamics**, **GenMark Diagnostics** (now part of Roche), and **C-N Biosciences** (now part of Merck). He also serves on the Board of Directors of several private high-technology companies, including **Nuclear RNA Networks**, an early-stage RNA gene transcription therapeutics company, and **Parabilis Space Technologies**, a global leader in hybrid solid-liquid rocket motors shaping the next era of responsive space operations. Raised $500MM+ in equity and debt capital in public and private offerings. He holds a B.S. from the University of Pennsylvania (Wharton School), MBA from the University of Arizona (Eller School).

RICHARD B. SLANSKY
Chief Financial Officer

FRANCESCO GALIMI
M.D., Ph.D., serving as Chief Medical Officer and Head of Development

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotech as well as large pharma companies. Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio**. Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at **GNF/Novartis**. Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

Highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation. Prior to joining Genenta, she was Head of Finance at **OAM** – Financial Supervisory Authority, and she held CFO roles and was part of the Supervisory Body ex DLGS 231/01 of a public company in the renewable energy field. Former senior manager at **PWC**, in the industrial and service field. She earned a Master's degree at the University of Nicosia in Science of Digital Currency, a Degree as Strategic CFO at Harvard Business School, a Master's degree in Business and Administration at the University of Parma and she is a Chartered Public Accountant and Auditor.

BARBARA REGONINI
Finance Director

GIANFRANCO DE NIGRIS
Vice President Corporate Development

Educated at Bocconi University and the London School of Economics, He began his career as an Equity Analyst Intern at **Kairos Partners SGR – Julius Baer Group**, before moving into investment banking at **NM Rothschild & Sons**. He subsequently gained experience in private banking and wealth management at **Mediobanca**, **Banor SIM and Banca Generali**. Since 2023, he has served as Vice President Corporate Development at Genenta Science, where he manages relationships with global institutional investors, investment banks and analysts, partnering directly with the CEO.

Genenta
Science





- AEROSPACE
- DEFENSE

Genenta Science





AEROSPACE & DEFENSE

Genenta's defense and advanced manufacturing pillar will be built through the acquisition of **multiple privately held businesses** operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility.

ATC initial agreement signed in January 2026, wholly-owned subsidiary completed on May 29, 2026. Italian company operating as **high-precision manufacturer of tactical rifles and special-forces weapon systems, and competition-grade sporting firearms.**

June 25, 2026, **Sòphia High Tech ("Sòphia HT"):** entry at 19.9%, moving toward 51% (two-tranche structure). **Italian company manufacturing critical parts for Europe's space and defense programs.**

Genenta
Science



- AEROSPACE

Genenta Science

WHY SPACE, WHY NOW: THE STRATEGIC RATIONAL

The space economy is scaling rapidly, driven by commercial demand national security priority and sovereign

HISTORIC GROWTH IN ORBITAL LAUNCHES

Total orbital launches conducted by commercial launch providers



Source: BryceTech, Global Orbital Space Launches – 2025 Year in Review

2025 YEAR IN REVIEW

325
Orbital launches in 2025
+25% YoY

4,544
Spacecraft deployed in 2025
+54% YoY

87%
of launches performed by commercial providers

RECORD YEAR
Global launch activity

POWERFUL LONG-TERM DRIVERS

- Commercial satellite expansion
- Defense and national security demand
- Sovereign investment in strategic space capabilities
- Growing need for specialized manufacturing capacity

Every rocket launched, every satellite deployed and every next-generation defense platform ultimately depends on a highly specialized manufacturing supply chain.

That is where Sophia HT operates.

WHY SOPHIA HT

Sophia HT manufactures mission-critical, flight-qualified ..positioning **Genenta Science** within one of Europe's fastest-growing segments of the strategic industrial base.

Genenta Science

SOPHIA HIGH TECH: COMPANY OVERVIEW



What it does

- Builds the **critical mechanical components** of space and defense systems, precision parts that hold rockets together, protect satellites in orbit, and let aircraft perform under extreme stress.
- Covers the **entire product lifecycle:** concept design & simulation → prototyping → manufacturing → testing, assembly & flight qualification.

What sets it apart

- Mastery of **space manufacturing:** metal 3D printing (Selective Laser Melting), CNC precision machining & multitasking.
- **Advanced materials** (titanium, Inconel, tungsten, specialized copper alloys) plus proprietary new alloy R&D for space propulsion.

Certifications & credentials

- **EN9100** (aerospace quality) and **ECSS-Q-ST-70-80C** (ESA additive-manufacturing spec).
- One of the very few companies in Europe qualified to **3D-print flight-ready space hardware to ESA and NASA standards.**

Track record

- **530+ advanced projects completed.**
- Customers: **ESA, AVIO, Thales Alenia Space, Leonardo, MBDA, GSSI, D-Orbit,** plus prestigious automotive brands such as **Lamborghini.**

SOPHIA HT: KEY FIGURES



The transaction

- April 22, 2026 — Genenta signed an Investment Agreement with Sòphia HT to reach a controlling stake through a phased two-tranche structure.
- June 12, 2026 — Required Golden Power authorization obtained.
- June 25, 2026 — First tranche completed following satisfaction of all closing conditions; Genenta now holds 19.9% of Sòphia HT.

Structure & funding

- Total funding of € 6.0M in two tranches — the second tranche performance-driven taking Genenta to 51%.
- Proceeds to scale production capacity, accelerate technological differentiation, and strengthen commercial penetration[1].

Financial profile

- Already profitable, with a solid net cash position and disciplined management. FY2025: €8.47M Total Operating Revenues, €1.61M EBITDA, 19.0% margin. Total value of production, including €7.17M sales and €1.30M other operating income.
- Projecting growing revenues and continued EBITDA growth in 2026, 2027 and beyond[2].

1: See "Non-GAAP Information" for a discussion of the measure EBITDA 2: For additional information, please refer to our Form 6-K, filed with the Securities and Exchange Commission. Based on management estimates and current order pipeline; not audited; subject to execution, production capacity, customer timing, export authorizations, geopolitical developments and other risks described in the Company's SEC filings.

Genenta Science

SPACE MANUFACTURING



Genenta Science

CUSTOMERS & PROGRAMS



Genenta
Science



- DEFENSE

Genenta Science

DEFENSE MARKET CONTEXT

DEFENSE MARKET CONTEXT

THE DEFENSE INDUSTRIAL BASE IS EXPANDING STRUCTURALLY

Global defense spending is supported by sustained geopolitical priorities, long-term NATO commitments and unprecedented European industrial investment.

GLOBAL MILITARY EXPENDITURE (US$ TRILLION)[1]



$2.89T
Global military expenditure in 2025

11
consecutive years of growth

Source: SIPRI

Source: SIPRI Military Expenditure Database (April 2025 & April 2026 Releases)

LONG-TERM STRUCTURAL DRIVERS

5% GDP
NATO members committed to increase defense and security-related spending by 2035

Source: NATO Summit Deciaration, The Hague, June 2025

Up to €800B
ReArm Europe / Readiness 2030
Largest European defense industrial initiative in decades

Source: European Commission

Defease budgets create value only once they translate into industrial production capacity.
Companies with certified manufacturing capabilities are positioned to benefit from this long-term investment cycle.
ATC provides Genenta with exposure to this specialized manufacturing layer of the defense industrial base.

Genenta Science

ATC: COMPANY OVERVIEW



- ATC "Armi Tattiche Custom" is an Italian company **founded in 2019.** ATC designs, engineers, and manufactures **high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories.** Through vertical integration of design and through final quality assurance, ATC provides fully customized, premium tactical systems. Its location in Northern Italy gives it access to advanced mechanical engineering talent and streamlined export logistics. ATC has established a commercial agreement in **Sofia (Bulgaria).**
- ATC conducts its core operations in Italy, including R&D, CAD/CAM design, precision CNC machining, finishing, assembly, and final tomographic inspection.
- ATC holds UAMA, SeRNI export-control licenses, NATO qualifications and authorization from the Italian Ministry of Defense[1].
- ATC products are used by special-forces units and include **combat-proven systems.** FY26 revenues are expected to be primarily driven by defense-related activities, including contracts with key institutional customers, notably in Ukraine.

1: UAMA is the Italian government authority responsible for authorizing and overseeing the export and transfer of defense-related materials under applicable Italian and international regulations.
SeRNI the Italian National Register of Defense and National Security Companies, certifies authorized defense and national security operators.

ATC: THE ACQUISITION



- **Timing:** January 2026 — Initial investment agreement signed. May 2026 — Genenta completed the acquisition of 100% of A.T.C. S.r.l. ("ATC").
- **100% acquired with no cash consideration**
  The acquisition was completed entirely through newly issued Genenta shares, preserving corporate liquidity and financial flexibility for future strategic investments and acquisitions.
- **Long-term alignment through a 36-month lock-up**
  Former ATC shareholders are subject to a three-year lock-up, aligning their economic interests with long-term value creation and eliminating near-term selling pressure following closing.
- **Entrepreneurs become long-term shareholders**
  Rather than monetizing their business for cash, the former owners have reinvested 100% of their proceeds into Genenta equity, demonstrating confidence in the long-term value creation potential of the broader industrial platform.
- **Structured downside protection without near-term capital commitment**
  A put option becomes exercisable only between the third and fifth anniversaries of closing, and only if the share price remains materially below the agreed reference value, limiting short-term financial exposure while providing long-term alignment.
- **Embedded upside through a highly favorable call option**
  If Genenta's share price appreciates materially, the Company retains the right to reacquire the issued shares at a predetermined price, allowing shareholders to benefit from future value creation while limiting dilution over time.
- **Disciplined transaction structure**
  The transaction was completed through a fixed-value, stock-for-stock exchange with no earn-outs or purchase-price adjustments, providing execution certainty, simplified integration and clear economic alignment from day one.

Genenta Science



BIOTECHNOLOGY

Genenta Science

GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY

Proprietary platform to provide durable and safe treatments for solid tumors

Temferon ™ is a one-time cell therapy designed to break the tumor-induced immune suppression by enabling sustained targeted expression of **therapeutic payload inside the tumor microenvironment (TME).**

Generating clinical proof of concept for breaking immune tolerance

TEM GBM Phase 1/2a study:

- **Phase 1 dosing completed** with 25 patients receiving Temferon.
- Favorable initial evidence of reprogramming of the tumor microenvironment.
- Potential ability to activate T cells which could then be enhanced by the use of immune checkpoint inhibitors.
- **Two patients** have been enrolled in the **TEM-LT long-term follow-up study, surviving three years** from the time of 1st surgery.

Genenta Science

SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS

Evaluable Patients Dosed with Temferon	25
Number of Patients survival > 1 year	19 (76%)
Number of Patients survival > 2 years[1]	8 (32%)
Number of Patients survival > 3 years	2 (8%)

Survival rate at 1 and 2 years since first surgery compared favorably with reference GBM Italian registry data[2] (56.4% alive at 1 year, 14.4% alive at 2 years), indicating a potential survival benefit in the TEM-GBM treated cohort.

1 – Data as of January 20, 2026.

2 – Tumor registry of Istituto Nazionale Carlo Besta, Italy - Courtesy of Dr. Eoli.

PARTNERSHIPS TO TAKE TO THE NEXT STAGE

PARTNERSHIPS TO TAKE TO THE NEXT STAGE

The Company has reached key clinical milestones that it believes may enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and strategic value. The Company has for some time been engaged with DC Advisory as its exclusive financial advisor to explore partnership opportunities for its biotechnology platform. To date, DC Advisory has not identified, and the Company is not in active discussions with, any potential strategic partner regarding Temferon or the platform; the Company nevertheless intends to continue pursuing such opportunities in light of the quality of the underlying science and the preliminary clinical data generated to date. Genenta continues to support and monitor its GBM clinical trial, which remains active, while pursuing a capital-efficient approach to advancing additional opportunities through partnerships. Genenta has shifted its biotech strategy to a partnership-driven model and does not plan to incur material additional clinical development costs unless supported by a strategic partner or dedicated external financing. As disclosed in the Company's relevant Form 6-K[1], the Board approved the termination of the Company's amended and restated license agreement with Ospedale San Raffaele (OSR), following a review of its strategic priorities and resource allocation, with no material termination fee or penalty expected other than accrued obligations.

1 – May 19, 2026.

Genenta Science

PRELIMINARY CLINICAL DATA IN µMGMT GBM

SAFETY AND TOLERABILITY

- Detectable and expectedly very **low levels of IFN-α** (pg/ml range) in plasma;
- **Manageable safety profile,** with adverse events commonly associated with autologous stem cell transplantation and glioblastoma;
- **No dose limiting toxicities** observed to date;
- Rapid engraftment and **hematological recovery** observed in all patients treated (n=25).

BIOLOGICAL ACTIVITY

- Temferon-derived cells were **detectable** at more than 24 months **post infusion;**
- **Temferon** progeny detected **inside the GBM** tumor;
- Intra-tumor **IFN-α release;**
- Evidence of a pro-inflammatory state in recurrent tumors from patients who underwent second surgery;
- **Reprogramming** of the myeloid compartment.

Genenta Science






PIERLUIGI PARACCHI, CEO

pierluigi.paracchi@genenta.com

www.genenta.com

Via dell'Annunciata 31 - 20121 Milan, Italy

© 2026 Genenta Science. All rights reserved worldwide

Genenta Science

APPENDIX

© 2026 Genenta Science. All rights reserved worldwide

Genenta Science

BOARD OF DIRECTORS

PIERLUIGI PARACCHI

Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University**.

Previously, he founded and led **Quantica SGR**, co-founded **Axòn Capital**, and served as Venture Consultant at **Sofinnova Partners**. He has also served on the Executive Committee of Federchimica–Assobiotec and is a Board Member of **InnovUp**.

Francesco Dagnino is Founder and Managing Partner of **LEXIA**. Specialized in **M&A, private equity, venture capital, and capital markets**, he assists funds, companies, and entrepreneurs in extraordinary transactions and provides strategic advice to listed issuers, Boards of Directors, and internal committees on corporate governance matters. He also supports activist investors in **stake acquisitions, proxy solicitations, and shareholder relations**. Recognized among the leading professionals in the Italian legal market, he is the author of numerous publications in corporate law and financial markets and a speaker at industry conferences.

FRANCESCO DAGNINO

Board Member

MIGUEL M. MUTTI

Board member

Senior executive with over 25 years of international experience in the pharmaceutical and investment banking sectors. He has a proven track record in corporate and business development, M&A, licensing, and general management, having led major growth, restructuring, and integration projects across Europe, Latin America, and Asia.

Currently, he serves as Managing Partner at **Sinergetica Healthcare**, a strategic consulting and investment firm focused on pharma, biotech, and medtech. Before that, he held senior leadership roles at **Lupin Limited, Grünenthal GmbH, Chemo Group, and Citigroup.**

Miguel combines strategic vision, financial expertise, and hands-on operational leadership, supported by an MBA from ISTUD and executive training at INSEAD.

Riccardo Palmisano holds a degree in Medicine. A manager with over 40 years of experience in the pharma and biotech sectors, with strong training in marketing, management, finance, and organization (SDA Bocconi).
Former CEO of **MolMed** (now AGC Biologics, 2015-2020) and VP/General Manager Italy of **Genzyme**, with senior/VP roles at **GSK, Sanofi, Shire, Menarini, and Farmitalia Carlo Erba.** President of Assobiotec (2016-2022), now Past President. Following MolMed acquisition, he served in different roles start-up innovative companies as **Betaglue** (Executive Chairman) and **Innovavector** (CEO). Currently Senior Advisor to private equity funds **Triton and Quadrivio**, Chairman of **Biotec Italia**, Board member of **Navita**, and advisor in the healthcare and life science space, including **Diasorin**.

RICCARDO PALMISANO

Board member

ARMON R. SHAREI

Ph.D., Board Member

Armon is Founder and CEO of **Portal Biotechnologies** and formerly CEO and Founder of **SQZ Biotechnologies** (NYSE: SQZ).

He led company from invention to post-IPO with over $300M in equity financing, $1Bn **Roche** collaboration, and three clinical trials.

Stanford University, CA BS, with Honors and Distinction in Chemical Engineering and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology. Post-Doctoral Fellow, Immunology at Harvard Medical School.

Genenta Science

FINANCIAL PROFILE

Cash & cash equivalents and marketable securities[1]	$ 33 MM
Expected cash runway[2]	More than 12 months
Number of shares outstanding[3]	48.2 MM
Average daily volume[4]	1.5 MM shares

1 – December 31, 2025.
2 – For additional information see the Company's Form 20-F filed with the SEC on March 31, 2026.
3 – As of May 29, 2026.
4 - At July 1, 2026 according to Yahoo Finance's key statistics listing.